JP2020520910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520910A5 JP2020520910A5 JP2019563379A JP2019563379A JP2020520910A5 JP 2020520910 A5 JP2020520910 A5 JP 2020520910A5 JP 2019563379 A JP2019563379 A JP 2019563379A JP 2019563379 A JP2019563379 A JP 2019563379A JP 2020520910 A5 JP2020520910 A5 JP 2020520910A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- naphthylidine
- pharmaceutical composition
- ethoxy
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 86
- -1 4- (2- (3,3-difluoro-3-phosphonopropoxy) ethoxy) -2-methylphenethyl Chemical group 0.000 claims description 52
- 239000002245 particle Substances 0.000 claims description 42
- 125000005605 benzo group Chemical group 0.000 claims description 40
- 108091006082 receptor inhibitors Proteins 0.000 claims description 38
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 36
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 35
- 229910052782 aluminium Inorganic materials 0.000 claims description 35
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 34
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 28
- 235000019260 propionic acid Nutrition 0.000 claims description 28
- 239000000725 suspension Substances 0.000 claims description 28
- 229940000425 combination drug Drugs 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 23
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 22
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 17
- 239000000594 mannitol Substances 0.000 claims description 17
- 235000010355 mannitol Nutrition 0.000 claims description 17
- 239000007983 Tris buffer Substances 0.000 claims description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 16
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 14
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 11
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 11
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 10
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 10
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 9
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 9
- 102000002698 KIR Receptors Human genes 0.000 claims description 9
- 108010043610 KIR Receptors Proteins 0.000 claims description 9
- 102000017578 LAG3 Human genes 0.000 claims description 9
- 101150030213 Lag3 gene Proteins 0.000 claims description 9
- 239000012272 PD-L2 inhibitor Substances 0.000 claims description 9
- 229940121654 pd-l2 inhibitor Drugs 0.000 claims description 9
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 8
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 8
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 8
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 4
- 230000009278 visceral effect Effects 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 description 12
- 125000004450 alkenylene group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000004957 naphthylene group Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 0 Cc1cc(C)c(CCc2cnc3C(N)=Ic(cc(*I)cc4)c4-c3c2)cc1 Chemical compound Cc1cc(C)c(CCc2cnc3C(N)=Ic(cc(*I)cc4)c4-c3c2)cc1 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 229940044665 STING agonist Drugs 0.000 description 1
- 229940124614 TLR 8 agonist Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060740A JP2023093524A (ja) | 2017-05-19 | 2023-04-04 | 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508474P | 2017-05-19 | 2017-05-19 | |
| US62/508,474 | 2017-05-19 | ||
| PCT/IB2018/053481 WO2018211453A1 (en) | 2017-05-19 | 2018-05-17 | Compositions comprising naphthyridine derivatives and aluminium adjuvant for use in treating solid tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060740A Division JP2023093524A (ja) | 2017-05-19 | 2023-04-04 | 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520910A JP2020520910A (ja) | 2020-07-16 |
| JP2020520910A5 true JP2020520910A5 (https=) | 2021-07-26 |
Family
ID=62597814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563379A Withdrawn JP2020520910A (ja) | 2017-05-19 | 2018-05-17 | 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 |
| JP2023060740A Pending JP2023093524A (ja) | 2017-05-19 | 2023-04-04 | 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060740A Pending JP2023093524A (ja) | 2017-05-19 | 2023-04-04 | 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11752162B2 (https=) |
| EP (1) | EP3624806A1 (https=) |
| JP (2) | JP2020520910A (https=) |
| KR (1) | KR20200007040A (https=) |
| CN (2) | CN110636848A (https=) |
| AR (1) | AR111760A1 (https=) |
| AU (2) | AU2018268420B2 (https=) |
| BR (1) | BR112019024260A2 (https=) |
| CA (1) | CA3062609A1 (https=) |
| CL (1) | CL2019003293A1 (https=) |
| MX (2) | MX2019013720A (https=) |
| TW (1) | TW201900166A (https=) |
| WO (1) | WO2018211453A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| AR111760A1 (es) * | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| EP0708772B1 (en) | 1993-07-15 | 2000-08-23 | Minnesota Mining And Manufacturing Company | IMIDAZO [4,5-c]PYRIDIN-4-AMINES |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| TW200526656A (en) | 2003-10-03 | 2005-08-16 | 3M Innovative Properties Co | Pyrazolopyridines and analogs thereof |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| EP2552410B1 (en) * | 2010-03-31 | 2018-10-24 | Stabilitech Biopharma Ltd | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| WO2011130379A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| ES2458355T3 (es) * | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| EP2532359A1 (en) | 2011-06-10 | 2012-12-12 | Affiris AG | CETP fragments |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| SG11201400210RA (en) | 2011-09-01 | 2014-03-28 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
| JP6411378B2 (ja) | 2013-02-01 | 2018-10-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| BE1022875B1 (fr) | 2014-03-26 | 2016-09-30 | Glaxosmithkline Biologicals S.A. | Compositions pour une immunisation contre staphylococcus aureus |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| KR102540008B1 (ko) | 2014-08-01 | 2023-06-02 | 쓰리엠 이노베이티브 프로퍼티즈 캄파니 | 종양을 치료하기 위한 방법 및 치료적 조합 |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CA3003943A1 (en) * | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
| AR111760A1 (es) * | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
-
2018
- 2018-05-15 AR ARP180101267A patent/AR111760A1/es not_active Application Discontinuation
- 2018-05-17 WO PCT/IB2018/053481 patent/WO2018211453A1/en not_active Ceased
- 2018-05-17 AU AU2018268420A patent/AU2018268420B2/en not_active Ceased
- 2018-05-17 EP EP18730857.2A patent/EP3624806A1/en not_active Withdrawn
- 2018-05-17 KR KR1020197037113A patent/KR20200007040A/ko not_active Ceased
- 2018-05-17 MX MX2019013720A patent/MX2019013720A/es unknown
- 2018-05-17 CN CN201880032524.5A patent/CN110636848A/zh active Pending
- 2018-05-17 BR BR112019024260A patent/BR112019024260A2/pt not_active IP Right Cessation
- 2018-05-17 US US16/614,280 patent/US11752162B2/en active Active
- 2018-05-17 CA CA3062609A patent/CA3062609A1/en active Pending
- 2018-05-17 JP JP2019563379A patent/JP2020520910A/ja not_active Withdrawn
- 2018-05-17 TW TW107116758A patent/TW201900166A/zh unknown
- 2018-05-17 CN CN202310419489.5A patent/CN116473981A/zh active Pending
-
2019
- 2019-11-15 CL CL2019003293A patent/CL2019003293A1/es unknown
- 2019-11-15 MX MX2023004381A patent/MX2023004381A/es unknown
-
2021
- 2021-06-01 AU AU2021203564A patent/AU2021203564B2/en not_active Ceased
-
2023
- 2023-04-04 JP JP2023060740A patent/JP2023093524A/ja active Pending
- 2023-07-28 US US18/360,909 patent/US20240009215A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520910A5 (https=) | ||
| US20240084013A1 (en) | Use of Combination of Anti-PD-1 Antibody and VEGFR Inhibitor in Preparation of Drug for Treating Cancers | |
| ES2905823T3 (es) | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres | |
| US20220339169A1 (en) | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist | |
| CA3068836A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| KR20230006568A (ko) | 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법 | |
| ES3058652T3 (en) | Formulations for administration of eflornithine | |
| JP2014514346A5 (https=) | ||
| JP7028765B2 (ja) | ベンズアミドおよび活性化合物組成物および使用方法 | |
| CN121154828A (zh) | 使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法 | |
| US20140051662A1 (en) | Treatment of multiple myeloma with masitinib | |
| US20210330642A1 (en) | Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule | |
| KR20190104524A (ko) | 당원축적질환의 치료 방법 | |
| WO2023217268A1 (zh) | 抗tim-3抗体与抗pd-1抗体的药物组合 | |
| JP2006070032A (ja) | 抗血管形成薬剤組成物 | |
| US20210267972A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies | |
| JP2021530488A5 (https=) | ||
| TWI812820B (zh) | 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法 | |
| JP2020518649A5 (https=) | ||
| TW202011959A (zh) | 用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合 | |
| JP7080234B2 (ja) | ベンズアミドおよび活性化合物組成物および使用方法 | |
| JP2009520774A (ja) | コンブレタスタチンおよび抗癌剤を含む組合せ | |
| RU2022133736A (ru) | Композиции, содержащие производные нафтиридина и алюмосодержащее вспомагательное средство, предназначенные для применения в лечении солидных опухолей | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| WO2023274275A1 (zh) | 药物组合及其用途 |